{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:43:44Z","timestamp":1795085024164,"version":"4.10.2"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"S4","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Most patients with hepatocellular carcinoma (HCC) have liver cirrhosis, which develops following long periods of chronic liver disease. Cirrhosis is characterized by a decrease in hepatocyte proliferation, indicating an exhaustion of the regenerative capacity of the liver, and results in an increase in fibrous tissue and a destruction of liver cells, which may ultimately lead to the development of cancerous nodules. Half of all cases of HCC are associated with hepatitis B virus infection, with a further 25% associated with hepatitis C virus. Other risk factors for developing HCC include alcoholic liver disease, nonalcoholic steatohepatitis, intake of aflatoxin-contaminated food, diabetes, and obesity. There are multiple factors involved in the etiology of HCC, all of which have a direct impact on patient characteristics and disease course, and although a causative agent can often be identified, HCC remains an extremely complex condition associated with a poor prognosis. Additionally, the geographic variation in etiology means that information from different countries is needed in order to optimize surveillance methods and develop effective chemoprevention strategies. Unfortunately, there are still many gaps in our current understanding, and further research efforts are needed to fully elucidate the diverse mechanisms involved in the pathogenesis of HCC and offer optimal prevention strategies for those at risk.<\/jats:p>","DOI":"10.1634\/theoncologist.2010-s4-14","type":"journal-article","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T07:07:48Z","timestamp":1291014468000},"page":"14-22","source":"Crossref","is-referenced-by-count":387,"title":["The Etiology of Hepatocellular Carcinoma and Consequences for Treatment"],"prefix":"10.1093","volume":"15","author":[{"given":"Arun J.","family":"Sanyal","sequence":"first","affiliation":[{"name":"a Virginia Commonwealth University Medical Center, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Kew","family":"Yoon","sequence":"additional","affiliation":[{"name":"b The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lencioni","sequence":"additional","affiliation":[{"name":"c Pisa University School of Medicine, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,11,1]]},"reference":[{"issue":"suppl 1","key":"2021122207553346500_R1","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1111\/j.1440-1746.2007.05293.x","article-title":"Alcohol, cofactors and the genetics of hepatocellular carcinoma","volume":"23","author":"Yu","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"2021122207553346500_R2","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"2021122207553346500_R3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(09)70241-4","article-title":"Management of hepatocellular carcinoma in Asia: Consensus statement from the Asian Oncology Summit 2009","volume":"10","author":"Poon","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122207553346500_R4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2002.tb04090.x","article-title":"Epidemiology, risk factors, and natural history of hepatocellular carcinoma","volume":"963","author":"Montalto","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"2021122207553346500_R5","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.3748\/wjg.14.4300","article-title":"Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis","volume":"14","author":"Gomaa","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"suppl 4","key":"2021122207553346500_R6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"The Oncologist"},{"key":"2021122207553346500_R7","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/hep.22269","article-title":"Hepatitis C virus infection: Molecular pathways to metabolic syndrome","volume":"47","author":"Sheikh","year":"2008","journal-title":"Hepatology"},{"key":"2021122207553346500_R8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF02893401","article-title":"Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis","volume":"10","author":"Szab\u00f3","year":"2004","journal-title":"Pathol Oncol Res"},{"key":"2021122207553346500_R9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/hep.20965","article-title":"Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells","volume":"42","author":"Aleffi","year":"2005","journal-title":"Hepatology"},{"key":"2021122207553346500_R10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/jhep.2001.23786","article-title":"Changes in Wnt\/beta-catenin pathway during regulated growth in rat liver regeneration","volume":"33","author":"Monga","year":"2001","journal-title":"Hepatology"},{"key":"2021122207553346500_R11","article-title":"Role of Wnt\/beta-catenin signaling in liver metabolism and cancer","author":"Monga","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"2021122207553346500_R12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1134\/S0006297908050039","article-title":"Human oncogenic viruses: Hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis","volume":"73","author":"Gurtsevitch","year":"2008","journal-title":"Biochemistry (Mosc)"},{"key":"2021122207553346500_R13","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/hep.510230510","article-title":"Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis","volume":"23","author":"Delhaye","year":"1996","journal-title":"Hepatology"},{"key":"2021122207553346500_R14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3748\/wjg.15.300","article-title":"Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence","volume":"15","author":"Caillot","year":"2009","journal-title":"World J Gastroenterol"},{"key":"2021122207553346500_R15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/157488807779317062","article-title":"Telomerase activation in liver regeneration and hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde?","volume":"2","author":"Wege","year":"2007","journal-title":"Curr Stem Cell Res Ther"},{"key":"2021122207553346500_R16","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1096\/fj.01-0977com","article-title":"Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis","volume":"16","author":"Wiemann","year":"2002","journal-title":"FASEB J"},{"key":"2021122207553346500_R17","first-page":"5021","article-title":"Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma","volume":"63","author":"Farazi","year":"2003","journal-title":"Cancer Res"},{"key":"2021122207553346500_R18","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1158\/0008-5472.CAN-05-4608","article-title":"Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression","volume":"66","author":"Farazi","year":"2006","journal-title":"Cancer Res"},{"key":"2021122207553346500_R19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/carcin\/18.5.1027","article-title":"p53 protein expression by hepatocarcinogens in the rat liver and its potential role in mitoinhibition of normal hepatocytes as a mechanism of hepatic tumour promotion","volume":"18","author":"Gijssel","year":"1997","journal-title":"Carcinogenesis"},{"key":"2021122207553346500_R20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"key":"2021122207553346500_R21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nm1377","article-title":"A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells","volume":"12","author":"Lee","year":"2006","journal-title":"Nat Med"},{"key":"2021122207553346500_R22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(95)91693-8","article-title":"Cancer progression and p53","volume":"346","author":"Carson","year":"1995","journal-title":"Lancet"},{"key":"2021122207553346500_R23","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3748\/wjg.14.1734","article-title":"Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma","volume":"14","author":"Matsuda","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2021122207553346500_R24","doi-asserted-by":"crossref","first-page":"10351","DOI":"10.1073\/pnas.94.19.10351","article-title":"Loss of the gene encoding mannose 6-phosphate\/insulin-like growth factor II receptor is an early event in liver carcinogenesis","volume":"94","author":"Yamada","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122207553346500_R25","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int J Cancer"},{"key":"2021122207553346500_R26","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3748\/wjg.14.1652","article-title":"Natural history of hepatitis-related hepatocellular carcinoma","volume":"14","author":"But","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2021122207553346500_R27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/(SICI)1097-4652(199911)181:2<188::AID-JCP2>3.0.CO;2-7","article-title":"Hepatitis B virus in hepatocarcinogenesis","volume":"181","author":"Feitelson","year":"1999","journal-title":"J Cell Physiol"},{"key":"2021122207553346500_R28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/aje\/155.4.323","article-title":"Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women","volume":"155","author":"Donato","year":"2002","journal-title":"Am J Epidemiol"},{"key":"2021122207553346500_R29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/eri.09.3","article-title":"Hepatitis C and diabetes: The inevitable coincidence?","volume":"7","author":"Lonardo","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2021122207553346500_R30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2003.11.056","article-title":"Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance","volume":"126","author":"Shintani","year":"2004","journal-title":"Gastroenterology"},{"key":"2021122207553346500_R31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.21703","article-title":"Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines","volume":"46","author":"Cua","year":"2007","journal-title":"Hepatology"},{"key":"2021122207553346500_R32","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1152\/ajpendo.2001.280.5.E745","article-title":"Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance","volume":"280","author":"Kern","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2021122207553346500_R33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0891-5849(96)00044-5","article-title":"Association between reactive oxygen species and disease activity in chronic hepatitis C","volume":"21","author":"De Maria","year":"1996","journal-title":"Free Radic Biol Med"},{"key":"2021122207553346500_R34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/j.gastro.2009.09.009","article-title":"Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells","volume":"138","author":"Tu","year":"2010","journal-title":"Gastroenterology"},{"key":"2021122207553346500_R35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MCG.0b013e3180381584","article-title":"Mechanisms of synergy between alcohol and hepatitis C virus","volume":"41","author":"Singal","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"2021122207553346500_R36","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hep.20626","article-title":"HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis","volume":"41","author":"Pineda","year":"2005","journal-title":"Hepatology"},{"key":"2021122207553346500_R37","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200411190-00009","article-title":"Hepatocellular carcinoma in HIV-infected patients: Epidemiological features, clinical presentation and outcome","volume":"18","author":"Puoti","year":"2004","journal-title":"AIDS"},{"key":"2021122207553346500_R38","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1023\/A:1005638500236","article-title":"Hepatocellular carcinoma in autoimmune hepatitis","volume":"45","author":"Park","year":"2000","journal-title":"Dig Dis Sci"},{"key":"2021122207553346500_R39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.22432","article-title":"Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening","volume":"48","author":"Yeoman","year":"2008","journal-title":"Hepatology"},{"key":"2021122207553346500_R40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3748\/wjg.15.578","article-title":"Hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"15","author":"Teufel","year":"2009","journal-title":"World J Gastroenterol"},{"key":"2021122207553346500_R41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"key":"2021122207553346500_R42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2001-12926","article-title":"Clinical features and natural history of nonalcoholic steatosis syndromes","volume":"21","author":"Falck-Ytter","year":"2001","journal-title":"Semin Liver Dis"},{"key":"2021122207553346500_R43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MOG.0b013e3282fbccf2","article-title":"Recent advances in nonalcoholic fatty liver disease","volume":"24","author":"Greenfield","year":"2008","journal-title":"Curr Opin Gastroenterol"},{"key":"2021122207553346500_R44","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/hep.510300604","article-title":"Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"30","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"2021122207553346500_R45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11892-007-0029-z","article-title":"NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes","volume":"7","author":"Bugianesi","year":"2007","journal-title":"Curr Diab Rep"},{"key":"2021122207553346500_R46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1503\/cmaj.045232","article-title":"Nonalcoholic fatty liver disease","volume":"172","author":"Adams","year":"2005","journal-title":"CMAJ"},{"key":"2021122207553346500_R47","doi-asserted-by":"crossref","first-page":"496s","DOI":"10.1200\/jco.2009.27.15_suppl.9552","article-title":"Retrospective claims database analysis of elderly compared with nonelderly patients (pts) with newly diagnosed hepatocellular carcinoma (HCC) [abstract 9552]","volume":"27","author":"Sanyal","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207553346500_R48","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"2021122207553346500_R49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1262-3636(07)70098-8","article-title":"The ins and outs of mitochondrial dysfunction in NASH","volume":"30","author":"Fromenty","year":"2004","journal-title":"Diabetes Metab"},{"key":"2021122207553346500_R50","first-page":"1754","article-title":"Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center study","volume":"55","author":"Abdel-Wahab","year":"2008","journal-title":"Hepatogastroenterology"},{"key":"2021122207553346500_R51","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/350429a0","article-title":"Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa","volume":"350","author":"Bressac","year":"1991","journal-title":"Nature"},{"key":"2021122207553346500_R52","first-page":"756","article-title":"Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation","volume":"74","author":"Heidelbaugh","year":"2006","journal-title":"Am Fam Physician"},{"key":"2021122207553346500_R53","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/gut.2007.133637","article-title":"Budd-Chiari syndrome and veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"57","author":"Valla","year":"2008","journal-title":"Gut"},{"issue":"suppl 3","key":"2021122207553346500_R54","first-page":"iii1","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults","volume":"52","author":"British Society of Gastroenterology","year":"2003","journal-title":"Gut"},{"key":"2021122207553346500_R55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.48.2.251","article-title":"Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis","volume":"48","author":"Bolondi","year":"2001","journal-title":"Gut"},{"key":"2021122207553346500_R56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122207553346500_R57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: The BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"2021122207553346500_R58","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Conclusions of the Barcelona-2000 EASL conference","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"2021122207553346500_R59","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"2021122207553346500_R60","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3748\/wjg.v12.i5.828","article-title":"Clinical practice guidelines for hepatocellular carcinoma: The first evidence based guidelines from Japan","volume":"12","author":"Makuuchi","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"suppl 4","key":"2021122207553346500_R61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.2010-S4-34","article-title":"Current approaches to the treatment of early hepatocellular carcinoma","volume":"15","author":"Ye","year":"2010","journal-title":"The Oncologist"},{"key":"2021122207553346500_R62","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cgh.2007.01.014","article-title":"Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival","volume":"5","author":"Leykum","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122207553346500_R63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1872-034X.2007.00216.x","article-title":"Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan","volume":"38","author":"Makuuchi","year":"2008","journal-title":"Hepatol Res"},{"key":"2021122207553346500_R64","article-title":"NCCN Clinical Practice Guidelines in Oncology","volume-title":"Hepatobiliary Cancers V.1.2010","author":"National Comprehensive Cancer Network"},{"key":"2021122207553346500_R65","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.5858\/132.11.1761","article-title":"Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?","volume":"132","author":"Guzman","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"2021122207553346500_R66","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1007\/s00535-009-0112-0","article-title":"Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis","volume":"44","author":"Kawada","year":"2009","journal-title":"J Gastroenterol"},{"key":"2021122207553346500_R67","first-page":"19","article-title":"Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma","volume":"54","author":"Hann","year":"2008","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2021122207553346500_R68","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122207553346500_R69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-3-540-69297-3_10","article-title":"Cancer prevention by vaccination against hepatitis B","volume":"181","author":"Chang","year":"2009","journal-title":"Recent Results Cancer Res"},{"key":"2021122207553346500_R70","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122207553346500_R71","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7326\/0003-4819-135-9-200111060-00009","article-title":"Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination","volume":"135","author":"Ni","year":"2001","journal-title":"Ann Intern Med"},{"key":"2021122207553346500_R72","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2007.02.055","article-title":"Two decades of universal hepatitis B vaccination in Taiwan: Impact and implication for future strategies","volume":"132","author":"Ni","year":"2007","journal-title":"Gastroenterology"},{"key":"2021122207553346500_R73","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jnci\/djp288","article-title":"Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: A 20-year follow-up study","volume":"101","author":"Chang","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 2","key":"2021122207553346500_R74","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S1542-3565(05)00713-5","article-title":"Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy","volume":"3","author":"Omata","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122207553346500_R75","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-S4-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-S4-14","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/S4\/14\/41843767\/oncolo_15_s4_14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/S4\/14\/41843767\/oncolo_15_s4_14.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T07:40:04Z","timestamp":1640158804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/S4\/14\/6398937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,1]]},"references-count":75,"journal-issue":{"issue":"S4","published-online":{"date-parts":[[2010,11,1]]},"published-print":{"date-parts":[[2010,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-s4-14","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,11,1]]},"published":{"date-parts":[[2010,11,1]]}}}